Identifying markers to predict treatment response in bile duct cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to identify prognostic and predictive markers that can help determine how patients with bile duct cancer respond to various treatments, including surgery, chemotherapy, and targeted therapies. It is a multi-center, cohort study that will collect data from patients diagnosed between 2003 and 2030, with a follow-up period of 10 years from the initial diagnosis. The study will evaluate the effectiveness and tolerance of current treatment practices and will include both retrospective and prospective data collection methods.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All locations of primitives (intrahepatic CCA, extrahepatic CCA, adenocarcinoma of the gallbladder; ampullomas excluded)
* Age \> 18 years
* Diagnosed between 2003 and 2030 (minimum follow-up 2 years)
* Written written non-opposition +/- signed informed consent for genetic studies (N.B.:

exemption requested for a deceased patient) N.B. Authorized inclusion in a therapeutic research protocol

Exclusion Criteria:

* Patient under guardianship, curatorship or legal protection
* Pregnant or breastfeeding women
* Any medical, psychological or social situation, which could prevent the compliance with the protocol according to the investigator's assessment
* Refusal to participate in the study

Where it's running

• CHU Hôpital Sud Amiens
  Amiens, France Recruiting
• CHU Angers
  Angers, France Recruiting
• CHU Besançon
  Besançon, France Recruiting
• Hôpital Avicenne
  Bobigny, France Recruiting
• CHU - Henri Mondor
  Créteil, France Recruiting
• CHU Dijon
  Dijon, France Recruiting

Study contacts

• Principal investigator: Cindy Neuzillet, Dr — Institut Curie, Saint-Cloud
• Study coordinator: Cindy Neuzillet, Dr
• Email: cindy.neuzillet@curie.fr
• Phone: +33 (0)1 47 11 15 15

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sintilimab with NALIRIFOX or GP as first-line treatment for metastatic biliary tract cancer

  This study tests whether adding sintilimab to either NALIRIFOX or gemcitabine‑cisplatin can help people with metastatic biliary tract cancer who have not had prior systemic therapy.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07831993

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• Liposomal irinotecan with 5-FU/LV and sintilimab plus SBRT for unresectable biliary tract cancer

  This trial tests whether combining liposomal irinotecan, 5-FU/LV, and sintilimab, followed by SBRT, can help patients with unresectable locally advanced biliary tract cancer become eligible for surgery or slow disease progression.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07797816

• Futibatinib and immunotherapy with chemo as first-line treatment for advanced biliary tract cancer

  A first-line treatment test combines Futibatinib with Zimberelimab and Gemcitabine/Cisplatin to see if it improves survival in people with unresectable or advanced biliary tract cancer.

  Recruiting at 4 sites Phase 3 Taiho Pharmaceutical Co., Ltd. · Brisbane and 20 other locations · NCT07710885

• ctDNA-guided precision care for lung, GIST, colorectal, biliary, and ovarian cancers

  This trial tests a blood test that looks for tumor DNA in patients with several cancers to help guide personalized treatment decisions.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT07673861

• Dual-target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

  This trial tests a ready-to-use CAR-NK cell therapy that targets HER2 and CEACAM5 in adults with unresectable or metastatic biliary tract cancers after standard therapy to see if it can help control the disease.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07641036

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.